Indivior stock heads into the open after a flat Nasdaq close
Published on 09/21/2026 at 06:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior stock closed around USD 34.88 on Nasdaq on September 18, 2026, essentially flat versus the prior session in a calm trading day for the specialty pharmaceuticals name. The latest data point leaves the shares broadly aligned with recent moves in the wider healthcare sector, which also saw only modest percentage changes on that date.
September 18, 2026 in numbers
Indivior PLC (ISIN GB00BYZ0C031, Nasdaq: INDV) most recently showed a Nasdaq price of USD 34.88 tied to the September 18, 2026 session, with the level appearing unchanged in market summaries for that day. Per recent market snapshots from MarketBeat data cited in sector commentary, the shares opened at USD 34.88 on Nasdaq and then held close to that figure through the September 18, 2026 trading session, implying a daily change of roughly 0.0 percent against the prior close, with intraday moves contained within a narrow trading range that kept the price near the mid-30s in USD terms. A sector screen referenced in a Faircurve healthcare overview on September 19, 2026 listed Indivior with a last close of USD 34.88, situating the stock comfortably within its current 52-week band and signaling that the September 18, 2026 session did not mark an extreme in either direction for the shares.
In that Faircurve screen, Indivior was shown with a model-derived fair value of USD 40.63 and a positive gap of 16.5 percent, which framed the USD 34.88 close on September 18, 2026 as below that valuation benchmark and helped explain why some investors treated the stock as undervalued in that framework. As Ad-hoc-news reported on September 20, 2026, the same Faircurve analysis underscored that the gap between the actual price and the model value remained notable even though the model confidence was described as low, adding a valuation angle to the otherwise quiet trading pattern around the September 18, 2026 close.
Today's focus on analyst views and valuation
Today, investors in Indivior stock are paying particular attention to analyst sentiment and valuation context ahead of the open. As MarketBeat noted on September 20, 2026, Indivior carries a consensus recommendation of Moderate Buy from seven firms currently covering the stock, with an average 12-month price target around USD 45.17 that sits clearly above the USD 34.88 area of the September 18, 2026 close. The same Ad-hoc-news commentary emphasized that this upside versus the analyst target range and the Faircurve fair value estimate forms a key part of the narrative around the stock into today's session, even as no specific company event such as earnings or a capital markets day is scheduled to take place on September 21, 2026. With the shares having closed at USD 34.88 on September 18, 2026 and the broader market still digesting sector trends, the contrast between the current trading level and the various valuation markers is set to remain an important reference point for Indivior stock as the new trading day gets underway.
